Indore Online Journal

Gouty Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx

 Breaking News
  • No posts were found

Gouty Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx

April 16
12:55 2024
Gouty Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx
The Gouty Arthritis Market Forecast report offers an in-depth understanding of the Gouty Arthritis, historical and forecasted epidemiology as well as the Gouty Arthritis market trends in the 7MM.

DelveInsight’s “Gouty Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gouty Arthritis, historical and forecasted epidemiology as well as the Gouty Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gouty Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gouty Arthritis Market Forecast

 

Some of the key facts of the Gouty Arthritis Market Report: 

  • The Gouty Arthritis market size is estimated to grow at a significant CAGR during the study period (2019-2032)
  • In October 2023, Atom Bioscience, a biotechnology firm based in China, has administered the initial dose to the first patient in a Phase IIb/III clinical trial of ABP-671 for the treatment of chronic gout, a prevalent form of inflammatory arthritis. This randomized, multi-center, double-blind study aims to enroll 580 patients from the United States and other countries.
  • In October 2023, Selecta Biosciences, Inc. has announced an agreement to transfer the manufacturing and development rights, along with the remaining clinical operations, of ImmTOR for SEL-212 to its partner in development and commercialization, Swedish Orphan Biovitrum AB (publ.) (Sobi). Effective November 6, 2023, Sobi will assume responsibility for manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is being developed for the treatment of chronic refractory gout.
  • Over 1.2 million cases of Gouty Arthritis were reported to be prevalent in the 7MM in 2021, with the United States reporting the largest number of cases. 
  • There were over 241,000 Gouty Arthritis cases diagnosed in the US in 2021, and over 460,000 cases in the EU-5. During the projected period (2022–2032), there is expected to be an increase in these numbers.
  • Gouty Arthritis affected women more than it did men, according to DelveInsight’s data. For example, in Japan in 2021, there were about 21,000 cases of Gouty Arthritis in males and about 29,000 in females.
  • Key Gouty Arthritis Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others
  • Key Gouty Arthritis Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab and others
  • The Gouty Arthritis epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases
  • The Gouty Arthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gouty Arthritis pipeline products will significantly revolutionize the Gouty Arthritis market dynamics.

 

Gouty Arthritis Overview

Gouty arthritis, commonly referred to as gout, is a form of inflammatory arthritis caused by the accumulation of urate crystals in the joints. These crystals form when there is an excess of uric acid in the blood, which can occur due to various factors such as genetics, diet, and lifestyle choices. Gout typically affects the big toe, causing intense pain, swelling, redness, and warmth in the affected joint.

 

Get a Free sample for the Gouty Arthritis Market Report: 

https://www.delveinsight.com/report-store/gouty-arthritis-gout-market

 

Gouty Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gouty Arthritis Epidemiology Segmentation:

The Gouty Arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Gouty Arthritis
  • Prevalent Cases of Gouty Arthritis by severity
  • Gender-specific Prevalence of Gouty Arthritis
  • Diagnosed Cases of Episodic and Chronic Gouty Arthritis

 

Download the report to understand which factors are driving Gouty Arthritis epidemiology trends @ Gouty Arthritis Epidemiology Forecast

 

Gouty Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gouty Arthritis market or expected to get launched during the study period. The analysis covers Gouty Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gouty Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gouty Arthritis Therapies and Key Companies

  • ILUMYA: Sun Pharma
  • Deucravacitinib: Bristol-Myers Squibb
  • Bimekizumab: UCB Biopharma
  • Izokibep: Affibody AB
  • SUNPG18_07: Sun Pharmaceutical Industries Limited
  • VTX958: Ventyx Biosciences, Inc
  • ATI-450: Aclaris Therapeutics, Inc.
  • Risankizumab: AbbVie
  • Upadacitinib: AbbVie
  • AIN457: Novartis
  • Ustekinumab: Janssen Research & Development, LLC
  • Sonelokimab: MoonLake Immunotherapeutics AG

 

Discover more about therapies set to grab major Gouty Arthritis market share @ Gouty Arthritis Treatment Market

 

Gouty Arthritis Market Strengths

  • Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of Gouty Arthritis in the recent decade
  • Various screening tools, including self-administered questionnaires, have been developed to help dermatologists, rheumatologist, and general physicians to identify patients who might suffer from Gouty Arthritis

 

Gouty Arthritis Market Unmet Needs

  • Lack of biomarkers
  • Challenges in current treatment options
  • Challenges in current guidelines
  • Poor disease understanding
  • Challenges in managing comorbidities

 

Scope of the Gouty Arthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Gouty Arthritis Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others
  • Key Gouty Arthritis Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others
  • Gouty Arthritis Therapeutic Assessment: Gouty Arthritis current marketed and Gouty Arthritis emerging therapies
  • Gouty Arthritis Market Dynamics: Gouty Arthritis market drivers and Gouty Arthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gouty Arthritis Unmet Needs, KOL’s views, Analyst’s views, Gouty Arthritis Market Access and Reimbursement 

 

To know more about Gouty Arthritis companies working in the treatment market, visit @ Gouty Arthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gouty Arthritis Market Report Introduction

2. Executive Summary for Gouty Arthritis

3. SWOT analysis of Gouty Arthritis

4. Gouty Arthritis Patient Share (%) Overview at a Glance

5. Gouty Arthritis Market Overview at a Glance

6. Gouty Arthritis Disease Background and Overview

7. Gouty Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gouty Arthritis 

9. Gouty Arthritis Current Treatment and Medical Practices

10. Gouty Arthritis Unmet Needs

11. Gouty Arthritis Emerging Therapies

12. Gouty Arthritis Market Outlook

13. Country-Wise Gouty Arthritis Market Analysis (2019–2032)

14. Gouty Arthritis Market Access and Reimbursement of Therapies

15. Gouty Arthritis Market Drivers

16. Gouty Arthritis Market Barriers

17.  Gouty Arthritis Appendix

18. Gouty Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories